2256 GMT - Funding risk is growing for Sonic Healthcare, says UBS. "While management has historically deemed U.S. and German funding reforms as unlikely, we believe growing policy momentum makes that view increasingly difficult to sustain," UBS says. In the U.S., PAMA reimbursement cuts have been proposed. These would reduce earnings by A$15 million, UBS says. In Germany, the local laboratory association has warned reforms could reduce private billing revenues by 34%. "Notably, the debate has shifted from whether reform proceeds to how severe the impact will be," UBS says. "We remain more optimistic than the industry's assumptions, modelling a 4% revenue headwind." Sonic ended last week at A$18.46. The stock is down 22% from its mid-August high.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.